Vantia Therapeutics appoints Andrew Crockett as Chief Executive Officer
Vantia Therapeutics announced that it has appointed Andrew Crockett to the position of Chief Executive Officer (CEO).
Since joining Vantia in 2009 as Vice President of Business Development, Mr Crockett has made a significant contribution to Vantia’s corporate development. Mr Crockett was previously with US specialty pharma company ZARS Pharma. During his career he has identified, negotiated and executed strategic corporate transactions on a global basis.
Mr Crockett holds an MBA from The Wharton School, University of Pennsylvania, with a major in Finance. He has served as an advisor to various investment groups for the medical device and pharmaceutical industries and is an advisory board member for several US-based start-ups.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.